CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
This Document Has Been Replaced By: Prevention and Control of Seasonal Influenza with Vaccines : Recommendations of the Advisory Committee on Immunization Practices — United States, 2017–18 Influenza Season
Superseded
This Document Has Been Replaced By: Prevention and Control of Seasonal Influenza with Vaccines : Recommendations of the Advisory Committee on Immunization Practices — United States, 2017–18 Influenza Season
Using Live, Attenuated Influenza Vaccine for Prevention and Control of Influenza; Supplemental Recommendations of the Advisory Committee on Immunization Practices (ACIP)
-
September 26, 2003
-
-
Source: Morbidity and Mortality Weekly Report (MMWR): Recommendations and Reports, 2003; v. 52, no. 13
Details:
-
Journal Article:Morbidity and Mortality Weekly Report (MMWR): Recommendations and Reports
-
Personal Author:
-
Corporate Authors:
-
Description:This report summarizes recommendations by the Advisory Committee on Immunization Practices (ACIP) for using intranasally administered, trivalent, cold-adapted, live, attenuated influenza vaccine (LAIV), which was approved for use in the United States on June 17, 2003 (FluMist trade mark, produced by MedImmune, Inc., Gaithersburg, Maryland). LAIV is currently approved for use among healthy persons (i.e., those not at high risk for complications from influenza infection) aged 5-49 years. This report includes information regarding 1) vaccine composition and mechanisms of action; 2) comparison between LAIV and trivalent inactivated influenza vaccine; 3) effectiveness and safety of LAIV; 4) transmission and stability of LAIV viruses; 5) recommendations and contraindications for using LAIV; and 6) dosage and administration of LAIV. This report supplements the 2003 ACIP recommendations regarding prevention and control of influenza (CDC. Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2003;52[No. RR-8]:1-36.)
-
Content Notes:Includes bibliographical references and index (p. 7-8).
-
Subjects:
-
Source:
-
Series:
-
ISSN:1057-5987 (print);1545-8601 (digital);
-
Pubmed ID:14557799
-
Document Type:
-
Genre:
-
Pages in Document:12 pdf pages
-
Volume:52
-
Issue:13
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type: